Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS.

Nicholas D. James,Nicholas D. James,Richard C. Coker,D. Tomlinson,J. Harris,M. Gompels,A. J. Pinching,J.S.W. Stewart

DOI: https://doi.org/10.1016/S0936-6555(05)80269-9

Clinics in Oncology

Abstract:

What problem does this paper attempt to address?

[Characteristics of left ventricular diastolic function in patients with hypertension].

B. Cai,L. Gong,J. Ye

Abstract:Left ventricular (LV) diastolic filling was examined by Doppler echocardiography in 239 patients with essential hypertension and 100 normal subjects. The Doppler study showed an inverse correlation between age and early diastolic peak velocity (PVE, r-0.201, P less than 0.05) [and a positive correlation between age and late diastolic peak velocity (PVA, r = 0.202, P less than 0.05) in normal subjects. Isovolumic relaxation time and late diastolic filling time were prolonged, PVA, A/E and Ai elevated, PVE, E/A and Ei/Ai as well as total filling time decreased in patients with hypertension as compared with the values found in the normal subjects (P less than 0.05 to 0.01). The results showed definite impairement of LV diastolic function in hypertensive patients. PVA correlated positively with systolic blood pressure (r = 0.68, P less than 0.01) and modestly with left atrial dimension in the hypertensives. No significant differences were found in FS and EF between the two study populations, indicating that LV filling abnormalities may occur early in patients with hypertension, even at a time when systolic performance has not yet been affected.
Nature-Inspired 1-Phenylpyrrolo[2,1-a]isoquinoline Scaffold for Novel Antiproliferative Agents Circumventing P-Glycoprotein-Dependent Multidrug Resistance

Alisa A. Nevskaya,Rosa Purgatorio,Tatiana N. Borisova,Alexey V. Varlamov,Lada V. Anikina,Arina Yu. Obydennik,Elena Yu. Nevskaya,Mauro Niso,Nicola A. Colabufo,Antonio Carrieri,Marco Catto,Modesto de Candia,Leonid G. Voskressensky,Cosimo D. Altomare

DOI: https://doi.org/10.3390/ph17040539

IF: 4.6

2024-04-23

Pharmaceuticals

Abstract:Previous studies have shown that some lamellarin-resembling annelated azaheterocyclic carbaldehydes and related imino adducts, sharing the 1-phenyl-5,6-dihydropyrrolo[2,1-a]isoquinoline (1-Ph-DHPIQ) scaffold, are cytotoxic in some tumor cells and may reverse multidrug resistance (MDR) mediated by P-glycoprotein (P-gp). Herein, several novel substituted 1-Ph-DHPIQ derivatives were synthesized which carry carboxylate groups (COOH, COOEt), nitrile (CN) and Mannich bases (namely, morpholinomethyl derivatives) in the C2 position, as replacements of the already reported aldehyde group. They were evaluated for antiproliferative activity in four tumor cell lines (RD, HCT116, HeLa, A549) and for the ability of selectively inhibiting P-gp-mediated MDR. Lipophilicity descriptors and molecular docking calculations helped us in rationalizing the structure–activity relationships in the P-gp inhibition potency of the investigated 1-Ph-DHPIQs. As a main outcome, a morpholinomethyl Mannich base (8c) was disclosed which proved to be cytotoxic to all the tested tumor cell lines in the low micromolar range (IC50 < 20 μM) and to inhibit in vitro the efflux pumps P-gp and MRP1 responsible for MDR, with IC50s of 0.45 and 12.1 μM, respectively.

pharmacology & pharmacy,chemistry, medicinal
Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Wen-Han Xue,Kai-Li Liu,Ting-Jian Zhang,Gang Dong,Jia-Hui Wang,Jing Wang,Shuai Guo,Jie Hu,Qing-Yu Zhang,Xin-Yang Li,Fan-Hao Meng,Wen-han Xue,Kai-li Liu,Ting-jian Zhang,Jia-hui Wang,Qing-yu Zhang,Xin-yang Li,Fan-hao Meng

DOI: https://doi.org/10.1016/j.ejmech.2023.116039

IF: 7.088

2023-12-14

European Journal of Medicinal Chemistry

Abstract:P-glycoprotein (P-gp) is an important factor leading to multidrug resistance (MDR) in cancer treatment. The co-administration of anticancer drugs and P-gp inhibitors has been a treatment strategy to overcome MDR. In recent years, tyrosine kinase inhibitor Lapatinib has been reported to reverse MDR through directly interacting with ABC transporters. In this work, a series of P-gp inhibitors ( 1-26 ) was designed and synthesized by integrating the quinazoline core of Lapatinib into the molecule framework of the third-generation P-gp inhibitor Tariquidar . Among them, compound 14 exhibited better MDR reversal activity than Tariquidar . The docking results showed compound 14 displayed the L-shaped molecular conformation. Importantly, compound 14 increased the accumulation of Adriamycin (ADM) and rhodamine 123 (Rh123) in MCF7/ADM cells. Besides, compound 14 significantly increased ADM-induced apoptosis and inhibited the proliferation, migration and invasion of MCF7/ADM cells. It was also demonstrated that compound 14 significantly inhibited the growth of MCF7/ADM xenograft tumors by increasing the sensitivity of ADM. In summary, compound 14 has the potential to overcome MDR caused by P-gp.

chemistry, medicinal
Novel pyxinol amide derivatives bearing an aliphatic heterocycle as P-glycoprotein modulators for overcoming multidrug resistance

Liping Yu,Ruiyin Ren,Shuang Li,Chen Zhang,Cheng Chen,Hanqi Lv,Zongji Zou,Xinjie Pei,Zhihua Song,Peng Zhang,Hongbo Wang,Gangqiang Yang

DOI: https://doi.org/10.1016/j.ejmech.2024.116466

IF: 7.088

2024-05-03

European Journal of Medicinal Chemistry

Abstract:P-glycoprotein (Pgp) modulators are promising agents for overcoming multidrug resistance (MDR) in cancer chemotherapy. In this study, via structural optimization of our lead compound S54 (nonsubstrate allosteric inhibitor of Pgp), 29 novel pyxinol amide derivatives bearing an aliphatic heterocycle were designed, synthesized, and screened for MDR reversal activity in KBV cells. Unlike S54 , these active derivatives were shown to transport substrates of Pgp. The most potent derivative 4c exhibited promising MDR reversal activity (IC 50 of paclitaxel = 8.80 ± 0.56 nM, reversal fold = 211.8), which was slightly better than that of third-generation Pgp modulator tariquidar (IC 50 of paclitaxel = 9.02 ± 0.35 nM, reversal fold = 206.6). Moreover, the cytotoxicity of this derivative was 8-fold lower than that of tariquidar in human normal HK-2 cells. Furthermore, 4c blocked the efflux function of Pgp and displayed high selectivity for Pgp but had no effect on its expression and distribution. Molecular docking revealed that 4c bound preferentially to the drug-binding domain of Pgp. Overall, 4c is a promising lead compound for developing Pgp modulators.

chemistry, medicinal
Cutaneous and articular tuberculosis in a renal transplant recipient.

M. Moyses-Neto,D. Drumond,G. Morgantetti,T. M. Garcia,V. R. Bolella,E. A. Romão

DOI: https://doi.org/10.1590/0037-8682-0090-2016

2017-07-01

Revista da Sociedade Brasileira de Medicina Tropical

Abstract:Seven months after undergoing kidney transplantation, a 56-year-old woman presented with papules and ulcers in her right forearm. The patient received antibiotics for 8 months with limited improvement. Eleven months after symptom onset, she presented with acute arthritis in her left knee. Asynovial fluid culture yielded Mycobacterium tuberculosis, and a forearm ulcer biopsy showed granulomatous inflammation. After surgical fistulectomy and 12 months of tuberculosis treatment, she was cured. Chronic cutaneous ulcers and articular manifestations in TB are rare, but they should always be considered in the differential diagnosis for immunosuppressed patients. Surgical intervention and prolonged treatment might be necessary.
Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer

Safiulla Basha Syed,Hemant Arya,I-Hsuan Fu,Teng-Kuang Yeh,Latha Periyasamy,Hsing-Pang Hsieh,Mohane Selvaraj Coumar

DOI: https://doi.org/10.1038/s41598-017-08062-2

IF: 4.6

2017-08-11

Scientific Reports

Abstract:P-glycoprotein (P-gp) is a drug transporter that effluxes chemotherapeutic drugs and is implicated in the development of resistance of cancer cells to chemotherapeutic drugs. To date, no drug has been approved to inhibit P-gp and restore chemotherapy efficacy. Moreover, majority of the reported inhibitors have high molecular weight and complex structures, making it difficult to understand the basic structural requirement for P-gp inhibition. In this study, two structurally simple, low molecular weight piperine analogs Pip1 and Pip2 were designed and found to better interact with P-gp than piperine in silico. A one step, acid-amine coupling reaction between piperic acid and 6,7-dimethoxytetrahydroisoquinoline or 2-(3,4-dimethoxyphenyl)ethylamine afforded Pip1 and Pip2, respectively. In vitro testing in drug resistant P-gp overexpressing KB (cervical) and SW480 (colon) cancer cells showed that both analogs, when co-administered with vincristine, colchicine or paclitaxel were able to reverse the resistance. Moreover, accumulation of P-gp substrate (rhodamine 123) in the resistant cells, a result of alteration of the P-gp efflux, was also observed. These investigations suggest that the natural product analog – Pip1 ((2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1 H)-yl)penta-2,4-dien-1-one) – is superior to piperine and could inhibit P-gp function. Further studies are required to explore the full potential of Pip1 in treating drug resistant cancer.

multidisciplinary sciences
Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells.

Baoan Chen,Li Yin,Jian Cheng,Jiahua Ding,Chong Gao,Yunyu Sun,Gang Zhao,Jun Wang,Wen Bao,Guohua Xia,Feng Gao,Xuemei Wang

DOI: https://doi.org/10.1179/102453311X12902908411797

IF: 2.264

2013-01-01

Hematology

Abstract:In this study, we applied D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) hydrochloride as a chemical inhibitor for glucosylceramide synthase (GCS) and tetrandrine (Tet) for P-glycoprotein (P-gp) to reverse daunorubicin (DNR) resistance of human leukemia cell line K562/A02. Cytotoxicity assays showed that either PDMP or Tet enhanced cytotoxic effect of DNR on K562/A02 cells, while cotreatment of these two drugs had a more significant effect on chemosensitization. Using flow cytometric analysis, we confirmed that the enhancement effect was accompanied by elevated cellular DNR accumulation and DNR-induced apoptosis. According to reverse transcription-polymerase chain reaction and western blot, the reversal effect of that composite might owe to the significant downregulation of mdr1 and GCS gene expressions. Importantly, PDMP diminished mdr1 gene expression and Tet also downregulated GCS gene expression. Moreover, a positive correlation was observed between GCS and P-gp. Thus, our results suggest that a potential clinical application of PDMP in combination with Tet may enhance chemosensitivity in leukemia.
Synthesis and Evaluation of Novel Podophyllotoxin Derivatives As Potential Antitumor Agents.

Wei-Hua Cheng,Bo Cao,Hai Shang,Cong Niu,Li-Ming Zhang,Zhong-Heng Zhang,Dan-Li Tian,Shi Zhang,Hong Chen,Zhong-Mei Zou

DOI: https://doi.org/10.1016/j.ejmech.2014.08.006

IF: 7.088

2014-01-01

European Journal of Medicinal Chemistry

Abstract:Cancer multidrug resistance (MDR) is a common cause of treatment failure in cancer patients. Increased expression of permeability glycoprotein (P-gp), which is also known as MDR-1, is the main cause of multidrug resistance. Podophyllotoxin derivatives hold great promise in the battle to overcome multidrug resistance, as they can induce cytotoxicity through multiple mechanisms. Here, we synthesized sixteen novel podophyllotoxin derivatives and evaluated their cytotoxicities in human cancer cell lines, HeLa, K562 and K562/A02. Some of these compounds were more potent than etoposide, a clinically relevant inhibitor of DNA repair enzymes. In particular, compound 5p exhibited the most potent activity toward drug-resistant K562/A02 cells, as it robustly inhibited tumor cell proliferation and induced apoptosis. Furthermore, preliminary investigation suggested that 5p inhibited the expression of MDR-1 in K562/A02 cells more effectively than etoposide.
Carbonic anhydrase XII inhibition overcomes P-glycoprotein-mediated drug resistance: a potential new combination therapy in cancer

Kathryn F. Tonissen,Sally-Ann Poulsen

DOI: https://doi.org/10.20517/cdr.2020.110

2021-01-01

Cancer Drug Resistance

Abstract:Intrinsic or acquired resistance to chemotherapy is a major hurdle in the treatment of cancer. One of the key mechanisms of resistance is the overexpression of the drug efflux transporter P-glycoprotein (Pgp). Pgp overexpression renders a large number of mechanistically unrelated chemotherapies ineffective. Targeting Pgp inhibition directly to overcome drug resistance, although conceptually and mechanistically attractive, has not translated to the clinic, in part because Pgp also has a critical protective function in many healthy tissues. It was recently discovered that carbonic anhydrase XII (CA XII), an enzyme associated with pH regulation in cancer, is co-expressed and co-located with Pgp in drug resistant cancer cells. CA XII is also upregulated by hypoxia, which is another microenvironmental factor that contributes to drug resistance. Here, we review findings that demonstrate modulation of CA XII may offer a promising new approach towards overcoming the longstanding hurdle of drug resistance and therapy failure against solid cancers. This review covers the use of CA XII inhibitors, both small molecule and antibody, in combination with chemotherapeutics that are substrates for Pgp. This combination therapy approach restores the efficacy of chemotherapy in resistant cells and offers a potential new therapeutic window to re-examine the targeting of Pgp as a safe, effective, and novel anticancer strategy.
Synthesis and evaluation of novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors for overcoming MDR in cancer

Jinyun Dong,YuLong Li,Zhiyuan Jin,Zumei Wu,Maohua Cai,Guangzhao Pan,Wenchong Ye,Wen Zhou,Zheshen Li,Sichao Tian,Zhe-Sheng Chen,Jiang-Jiang Qin

DOI: https://doi.org/10.1016/j.bmc.2024.117944

IF: 3.461

2024-10-13

Bioorganic & Medicinal Chemistry

Abstract:The emergence of multidrug resistance (MDR) in malignant tumors is one of the major threats encountered currently by many chemotherapeutic agents. Among the various mechanisms involved in drug resistance, P-glycoprotein (P-gp, ABCB1), a member of the ABC transporter family that significantly increases the efflux of various anticancer drugs from tumor cells, and the metabolic enzyme CYP1B1 are widely considered to be two critical targets in overcoming MDR. Unfortunately, no MDR modulator has been approved by the FDA to date. In this study, based on pharmacophore hybridization, bioisosteric and fragment-growing strategies, we designed and synthesized 11 novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors. Among them, the preferred compound A10 exhibited the best MDR reversal activity (IC 50 = 0.25 μM, RF = 44.4) in SW620/AD300 cells, being comparable to one of the most potent third P-gp inhibitor WK-X-34. In parallel, this dual ABCB1/CYP1B1 inhibitory effect drives compound A10 to exhibit a prominent drug resistance reversal activity to doxorubicin (IC 50 = 4.7 μM, RF = 13.7) in ABCB1/CYP1B1-overexpressing DOX-SW620/AD300-1B1 resistant cells, which is more potent than that of the CYP1B1 inhibitor ANF. Furthermore, although compound A2 possessed moderate ABCB1/CYP1B1 inhibitory activities, it showed considerable antiproliferative activity towards drug-resistant SW620/AD300 and MKN45-DDP-R cells, which may be related to the increase of PUMA expression to promote the apoptosis of the drug-resistant MKN45-DDP-R cells as confirmed by proteomics and western blot assay. These results indicated that tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates may provide a fundamental scaffold reference for further discovery of MDR reversal agents.

biochemistry & molecular biology,chemistry, medicinal, organic
Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms.

Ye Su,Xin Cheng,Yaohong Tan,Yunhui Hu,Yuan Zhou,Juanni Liu,Yuanfu Xu,Yinliang Xie,Caiyun Wang,Yingdai Gao,Jianxiang Wang,Tao Cheng,Chunzheng Yang,Dongsheng Xiong,Hua Miao

DOI: https://doi.org/10.1371/journal.pone.0032782

IF: 3.7

2012-01-01

PLoS ONE

Abstract:Multidrug resistance mediated by P-glycoprotein in cancer cells has been a major issue that cripples the efficacy of chemotherapy agents. Aimed for improved efficacy against resistant cancer cells, we designed and synthesized 25 oxindole derivatives based on indirubin by structure-activity relationship analysis. The most potent one was named PH II-7, which was effective against 18 cancer cell lines and 5 resistant cell lines in MTT assay. It also significantly inhibited the resistant xenograft tumor growth in mouse model. In cell cycle assay and apoptosis assay conducted with flow cytometry, PH II-7 induced S phase cell cycle arrest and apoptosis even in resistant cells. Consistently revealed by real-time PCR, it modulates the expression of genes related to the cell cycle and apoptosis in these cells, which may contributes to its efficacy against them. By side-chain modification and FITC-labeling of PH II-7, we were able to show with confocal microscopy that not only it was not pumped by P-glycoprotein, it also attenuated the efflux of Adriamycin by P-glycoprotein in MDR tumor cells. Real-time PCR and western blot analysis showed that PH II-7 down-regulated MDR1 gene via protein kinase C alpha (PKCA) pathway, with c-FOS and c-JUN as possible mediators. Taken together, PH II-7 is a dual-functional compound that features both the cytotoxicity against cancer cells and the inhibitory effect on P-gp mediated drug efflux.
Screening Novel, Potent Multidrug-Resistant Modulators from Imidazole Derivatives

LM Chen,XP Wu,JW Ruan,YJ Liang,Y Ding,Z Shi,XW Wang,LQ Gu,LW Fu

DOI: https://doi.org/10.3727/0965040041292378

2004-01-01

Abstract:The overexpression of P-glycoprotein (P-gp) by tumor cells results in multidrug resistance (MDR) to structurally unrelated anticancer drugs. Combined therapy with MDR-related cytotoxins and MDR modulators is a promising strategy to overcome clinical MDR. This study was designed to screen potent MDR modulators from imidazole derivatives. Cytotoxicity was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The intracellular accumulation of doxorubicin (Dox) was detected by fluorescence spectrophotometry. The function of P-gp was examined by Rhodamine 123 accumulation detected with flow cytometry (FCM). Among imidazole derivatives, FG020326, FG020327, and FG020318 were found to possess three- to fourfold stronger reversal MDR activity than verapamil, a well-known positive MDR modulator. Imidazole derivatives significantly increased the Dox accumulation and inhibited P-gp function exhibited by the increase of Rhodamine accumulation in MDR cells. The fold reversal of MDR was relative with the increase of Rhodamine accumulation. FG020326, FG020327, and FG020318 showed potent MDR reversal activity in vitro. Their mechanism of MDR reversal is associated with the inhibition of P-gp function and the increase of anticancer accumulation. These results suggest FG020326, FG020327, and FG020318 are promising to further study and develop.
Novel Benzo Five-Membered Heterocycle Derivatives as P-Glycoprotein Inhibitors: Design, Synthesis, Molecular Docking, and Anti-Multidrug Resistance Activity

Zhikun Yang,Yue Cai,Xue Yang,Yasheng Li,Qihao Wu,Yanlei Yu,Zhen Chen,Bin Wei,Jin-Miao Tian,Xiaoze Bao,Xinyi Ye,Jianwei Chen,Huawei Zhang,Xiaozhou Mou,Xuanrong Sun,Hong Wang

DOI: https://doi.org/10.1021/acs.jmedchem.2c01999

IF: 8.039

2023-04-05

Journal of Medicinal Chemistry

Abstract:A proposed strategy to overcome multidrug resistance (MDR) of anticancer drugs in chemotherapy is to disable the efflux function of P-glycoprotein (P-gp). In this study, based on ring-merging and fragment-growing strategies, 105 novel benzo five-membered heterocycle derivatives were designed, synthesized, and screened. Exploration of the structure-activity relationship (SAR) led to the identification of d7 with low cytotoxicity and promising reversal activity to doxorubicin in MCF-7/ADR cells....

chemistry, medicinal
Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety As Orally Bioavailable Reversal Agents Against P-Glycoprotein-Mediated Mutidrug Resistance.

Bo Wang,Li-Ying Ma,Jing-Quan Wang,Zi Ning Lei,Pranav Gupta,Yuan-Di Zhao,Zhong-Hua Li,Ying Liu,Xin-Hui Zhang,Ya-Nan Li,Bing Zhao,Zhe-Sheng Chen,Hong-Min Liu

DOI: https://doi.org/10.1021/acs.jmedchem.8b00335

IF: 8.039

2018-01-01

Journal of Medicinal Chemistry

Abstract:P-glycoprotein (ABCB1)-mediated multidrug resistance (MDR) has become a major obstacle in successful cancer chemotherapy, which attracted much effort to develop clinically useful compounds to reverse MDR. Here, we designed and synthesized a novel series of derivatives with a 5-cyano-6-phenylpyrimidine scaffold and evaluated their potential reversal activities against MDR. Among these compounds, 55, containing an acylurea appendage, showed the most potent activity in reversing paclitaxel resistance in SW620/AD300 cells. Further studies demonstrated 55 could increase accumulation of PTX, interrupt ABCB1-mediated Rh123 accumulation and efflux, stimulate ABCB1 ATPase activity, and especially have no effect on CYP3A4 activity, which avoid drug interaction caused toxicity. More importantly, 55 significantly enhanced the efficacy of PTX against the SW620/AD300 cell xenograft without obvious side effects for orally intake. Given all that, the pyrimidine-acylurea based ABCB1 inhibitor may be a promising lead in developing new efficacious ABCB1-dependent MDR modulator.
Design, Synthesis and In‐Silico Studies of Piperidine‐Dihydropyridine Hybrids as Anticancer Agents

Tanmoy Mondal,Swathi Rejinthalaa,Srinivas Endoori Srinivas Endoori,Vishnu Thumma

DOI: https://doi.org/10.1002/cbdv.202301456

2024-02-19

Chemistry & Biodiversity

Abstract:In this study, we designed, synthesized and characterized a novel series of piperidine‐dihydropyridine hybrid compounds and characterized them by 1H NMR, 13C NMR, mass spectrometry (MS), and elemental analysis. Subsequently, we assessed their in vitro anticancer potentials against the human breast adenocarcinoma cell line MCF‐7 and the lung cancer cell line A‐549. Several of these compounds demonstrated significant activity, with IC50 values ranging from 15.94 μM to 48.04 μM for A‐549 and 24.68 μM to 59.12 μM for MCF‐7, when compared to the reference drug Cisplatin. Notably, a compound featuring a 3‐fluoro substitution in the carboxamide series exhibited robust inhibitory effects, with an IC50 of 15.94 ± 0.201 μM against A‐549 cells and an IC50 of 22.12 ± 0.213 μM against MCF‐7 cells, respectively. Additionally, a compound containing a cyclobutyl ring displayed potent activity, with an IC50 of 16.56 ± 0.125 μM against A‐549 and an IC50 of 24.68 ± 0.217 μM against MCF‐7 cells, respectively. Furthermore, molecular docking studies against the Epidermal Growth Factor Receptor (EGFR) (PDB ID: 2J6M) revealed favourable binding scores and interactions, suggesting their potential as promising candidates for further investigation in the context of anticancer drug development.

chemistry, multidisciplinary,biochemistry & molecular biology
Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell

Ya-Sheng Li,Xi Yang,Dong-Sheng Zhao,Yue Cai,Zhi Huang,Rui Wu,Si-Jia Wang,Gui-Jun Liu,Jian Wang,Xiao-Ze Bao,Xin-Yi Ye,Bin Wei,Zi-Ning Cui,Hong Wang

DOI: https://doi.org/10.1016/j.ejmech.2021.113336

IF: 7.088

2021-04-01

European Journal of Medicinal Chemistry

Abstract:P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a phenomenon in which cells become resistant to structurally and mechanistically unrelated drugs resulting in low intracellular drug concentrations. It is one of the noteworthy problems in malignant tumor clinical therapeutics. So P-gp protein is one of the ideal targets to solve MDR. Based on the lead compound 5m obtained from our previous work, a series of furan derivatives featuring alkyl-substituted phenols and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline were designed and synthesized as reversal agents against P-gp in this paper. Compound 16 containing isopropoxy possessed good potency against P-gp mediated MDR in MCF-7/ADR (IC50 (doxorubicin) = 0.73 μM, RF = 69.6 with 5 μM 16 treated). Western blot results and Rh123 accumulation assays showed that 16 effectively inhibited P-gp efflux function but not its expression. The preliminary structure–activity relationship and docking studies demonstrated that compound 16 would be a potential P-gp inhibitor. Most worthy of mention is that compound 16 has achieved satisfactory results in combination with a variety of anti-tumor drugs, such as doxorubicin, paclitaxel, and vincristine. This study forwards a hopeful P-gp inhibitor for withstanding malignant tumor cell with multidrug resistance setting the basis for further studies.

chemistry, medicinal
Discovery of 2,5-disubstituted furan derivatives featuring a benzamide motif for overcoming P-glycoprotein mediated multidrug resistance in MCF-7/ADR cell

Zhikun Yang,Yue Cai,Shen Mao,Qihao Wu,Mengdi Zhu,Xiaoji Cao,Bin Wei,Jin-Miao Tian,Xiaoze Bao,Xinyi Ye,Jianwei Chen,Sijia Wang,Yanlei Yu,Huawei Zhang,Xuanrong Sun,Hong Wang,Zining Cui,Yasheng Li

DOI: https://doi.org/10.1016/j.ejmech.2023.115462

IF: 7.088

2023-05-14

European Journal of Medicinal Chemistry

Abstract:P-glycoprotein (P-gp) is one of the drug efflux transporters that triggers multidrug resistance (MDR) in cells. Herein, by utilizing the strategies of active skeleton splicing and structural optimization on the lead compound 5 m, a total of 50 novel 2,5-disubstituted furan derivatives were designed, synthesized, and screened for P-gp inhibitory activity. The structure-activity relationship analysis enabled the identification of an important pharmacophore N -phenylbenzamide, which resulted in the discovery of a promising drug lead compound III-8 . III-8 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells. Western blot and Rh123 accumulation assay demonstrated that III-8 displayed the reversal activity by inhibiting P-gp efflux. Molecular docking analysis indicated a potent affinity of III-8 to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. III-8 was determined to be a highly effective and safe P-gp inhibitor in an MCF-7/ADR xenograft mouse model.

chemistry, medicinal
4‐{3‐[(Pyridin‐4‐ylmethyl)amino]‐[1,2,4]triazolo[4,3‐b][1,2,4]triazin‐6‐yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator

Zahra Zakeri Khatir,Antonella Di Sotto,Ester Percaccio,Tuba Tuylu Kucukkilinc,Ayse Ercan,Ann M. Chippindale,Mehdi Valipour,Hamid Irannejad

DOI: https://doi.org/10.1002/ardp.202300704

2024-03-07

Archiv der Pharmazie

Abstract:A novel series of triazolotriazines substituted with CH2NH‐linked pyridine were designed for use as dual c‐Met/MDR inhibitors. Compound 12g inhibited P‐gp and MRP1/2 at 3 and 0.3 μM, respectively, in HepG2 and Bx‐PC3 cells, while it did not inhibit these two transporters in normal H69 cells at the same concentrations. Hepatocellular carcinoma is the most common type of primary liver cancer. However, multidrug resistance (MDR) is a major obstacle to the effective chemotherapy of cancer cells. This report documents the rational design, synthesis, and biological evaluation of a novel series of triazolotriazines substituted with CH2NH‐linked pyridine for use as dual c‐Met/MDR inhibitors. Compound 12g with IC50 of 3.06 μM on HepG2 cells showed more potency than crizotinib (IC50 = 5.15 μM) in the MTT assay. In addition, 12g inhibited c‐Met kinase at a low micromolar level (IC50 = 0.052 μM). 12g significantly inhibited P‐gp and MRP1/2 efflux pumps in both cancerous HepG2 and BxPC3 cells starting from the lower concentrations of 3 and 0.3 μM, respectively. 12g did not inhibit MDR1 and MRP1/2 in noncancerous H69 cholangiocytes up to the concentration of 30 and 60 μM, respectively. Current results highlighted that cancerous cells were more susceptible to the effect of 12g than normal cells, in which the inhibition occurred only at the highest concentrations, suggesting a further interest in 12g as a selective anticancer agent. Overall, 12g, as a dual c‐Met and P‐gp/MRP inhibitor, is a promising lead compound for developing a new generation of anticancer agents.

pharmacology & pharmacy,chemistry, medicinal, multidisciplinary
Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy

Henry Döring,David Kreutzer,Christoph Ritter,Andreas Hilgeroth

DOI: https://doi.org/10.3390/molecules26010018

IF: 4.6

2020-12-22

Molecules

Abstract:Despite the development of targeted therapies in cancer, the problem of multidrug resistance (MDR) is still unsolved. Most patients with metastatic cancer die from MDR. Transmembrane efflux pumps as the main cause of MDR have been addressed by developed inhibitors, but early inhibitors of the most prominent and longest known efflux pump P-glycoprotein (P-gp) were disappointing. Those inhibitors have been used without knowledge about the expression of P-gp by the treated tumor. Therefore the use of inhibitors of transmembrane efflux pumps in clinical settings is reconsidered as a promising strategy in the case of the respective efflux pump expression. We discovered novel symmetric inhibitors of the symmetric efflux pump MRP4 encoded by the ABCC4 gene. MRP4 is involved in many kinds of cancer with resistance to anticancer drugs. All compounds showed better activities than the best known MRP4 inhibitor MK571 in an MRP4-overexpressing cell line assay, and the activities could be related to the various substitution patterns of aromatic residues within the symmetric molecular framework. One of the best compounds was demonstrated to overcome the MRP4-mediated resistance in the cell line model to restore the anticancer drug sensitivity as a proof of concept.

chemistry, multidisciplinary,biochemistry & molecular biology
Design, Synthesis and Biological Evaluation of Biaryl Amide Derivatives As Modulators of Multi-Drug Resistance

Ying-Yuan Peng,Zhi-Xian Shi,Min Yu,Sami Karam,Zhi-Long Chen,Yang Wang

DOI: https://doi.org/10.1016/j.ejmech.2024.117090

IF: 7.088

2024-01-01

European Journal of Medicinal Chemistry

Abstract:The emergence of multi-drug resistance (MDR) presents a significant impediment to the efficacy of cancer treatment. Aberrant expression of ABC (ATP-binding cassette) transporters is acknowledged as one of the underlying factors contributing to MDR. P-glycoprotein (P-gp, MDR1, ABCB1), breast cancer resistance protein (BCRP, ABCG2), and MDR-associated protein 1 (MRP1, ABCC1) are members of the ABC transporter, and their over-expression usually occurs in drug-resistant tumor cells. In this work, the structure-activity relationships of the biaryl amide skeleton were systematically investigated via structural optimization step by step, which led to the identification of an exceptionally potent resistance reversal agent, D2. Compound D2 effectively reversed MDR to paclitaxel and cisplatin in A2780/T, A2780/CDDP and A549/T cell lines. It could directly bind to P-gp and downregulate the expression of both P-gp and MRP1. The treatment with D2 increased the intracellular accumulation of Rh123 and inhibited P-gp-mediated drug efflux of Rh123 in A2780/T cells. Therefore, compound D2 exhibits promising potential in overcoming multidrug resistance (MDR) induced by P-gp in cancer.

Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS.

[Characteristics of left ventricular diastolic function in patients with hypertension].

Nature-Inspired 1-Phenylpyrrolo[2,1-a]isoquinoline Scaffold for Novel Antiproliferative Agents Circumventing P-Glycoprotein-Dependent Multidrug Resistance

Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Novel pyxinol amide derivatives bearing an aliphatic heterocycle as P-glycoprotein modulators for overcoming multidrug resistance

Cutaneous and articular tuberculosis in a renal transplant recipient.

Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer

Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells.

Synthesis and Evaluation of Novel Podophyllotoxin Derivatives As Potential Antitumor Agents.

Carbonic anhydrase XII inhibition overcomes P-glycoprotein-mediated drug resistance: a potential new combination therapy in cancer

Synthesis and evaluation of novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors for overcoming MDR in cancer

Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms.

Screening Novel, Potent Multidrug-Resistant Modulators from Imidazole Derivatives

Novel Benzo Five-Membered Heterocycle Derivatives as P-Glycoprotein Inhibitors: Design, Synthesis, Molecular Docking, and Anti-Multidrug Resistance Activity

Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety As Orally Bioavailable Reversal Agents Against P-Glycoprotein-Mediated Mutidrug Resistance.

Design, Synthesis and In‐Silico Studies of Piperidine‐Dihydropyridine Hybrids as Anticancer Agents

Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell

Discovery of 2,5-disubstituted furan derivatives featuring a benzamide motif for overcoming P-glycoprotein mediated multidrug resistance in MCF-7/ADR cell

4‐{3‐[(Pyridin‐4‐ylmethyl)amino]‐[1,2,4]triazolo[4,3‐b][1,2,4]triazin‐6‐yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator

Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy

Design, Synthesis and Biological Evaluation of Biaryl Amide Derivatives As Modulators of Multi-Drug Resistance